MINNEAPOLIS, MN, US, Aug. 23, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that the Company has changed the brand name of its therapeutic osteoarthritis and lameness product to “SPRYNG”.
"We are incredibly excited to introduce to the world the new brand name for our therapeutic product that squarely addresses the debilitating impact of osteoarthritis and lameness in companion animals.” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “The brand name “SPRYNG” clearly illustrates how PetVivo’s product enhances the mobility and overall quality of life in dogs, horses and other animals."
Spryng™ with OsteoCushion™ Technology is a veterinary medical device comprised of millions of micronized hydrogel matrices, which are derived from the natural components collagen and elastin. OsteoCushion Technology provides both reinforcing natural joint support to replace missing and damaged cartilage as well as delivers natural scaffolding to help the healing of tissue defects. These attributes offer a great solution to the affliction of osteoarthritis for companion animals in a simple in-clinic treatment.
“We believe the brand name “SPRYNG” clearly depicts the beneficial results derived from our therapeutic product administered to animals suffering from osteoarthritis or other lameness afflictions,” said Russ Siakel, Director of Marketing for PetVivo Holdings, Inc. “We have truly witnessed the restoration of a “SPRYNG in the step” of companion animals that have received this life-changing product.”
Look at SPRYNG for managing the affliction, not just the symptoms of osteoarthritis. Visit www.petvivo.com to learn more about this amazing product.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.
John Lai, CEO
PetVivo Holdings, Inc.
Forward-Looking commercial Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company’s common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.